Hemophilia Market Research and Forecast Report 2022-2027

1. Global Hemophilia Market Research and Forecast Report 2022- 2027 Author: Elena Anderson Marketing Manager Copyright © IMARC Service Pvt Ltd. All Rights Reserved IMARC Group © 2022 IMARC All Rights Reserved

2. Report DescriptionAbout IMARC Group International Market Analysis Research and Consulting Group is a leading adviser on management strategy and market research worldwide. We partner with clients in all regions and industry verticals to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, chemicals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise. IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.

3. Report Description and Highlights Report Description Global Hemophilia Market Research Report 2022-2027: According to the latest report by IMARC Group, titled "Hemophilia Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027," the global hemophilia market reached a value of US$ 10.5 Billion in 2021. Hemophilia refers to a rare bleeding disorder wherein the blood does not clot normally, leading to spontaneous or excessive bleeding even from a minor injury. It is usually inherited and caused due to a hereditary lack of a coagulation factor which slows down the blood clotting process. It is associated with frequent nosebleeds, easy bruising, hematomas, and prolonged bleeding or oozing after an injury, surgery, and dental procedures. In severe cases, continuous bleeding may also occur following minor trauma or even in the absence of injury. Although there is no cure for hemophilia currently, the condition can be treated using replacement therapy, medications, and injections of a clotting factor or plasma. Hemophilia treatment focuses on replacing the missing protein and preventing complications, which is escalating its demand across the globe. Request market/requestsample for a PDF sample of this report: https://www.imarcgroup.com/hemophilia-

4. Report Description and Highlights Report Description Global Hemophilia Market Trends: The surging number of hemophilic patients and the rising incidences of genetic abnormalities represent the primary factors driving the market growth. Besides this, the increasing diagnosis rates and the widespread usage of prophylactic treatment for hemophilia are other major growth-inducing factors. Additionally, governing agencies of various countries are launching campaigns to spread awareness regarding the benefits of early diagnosis and taking favorable initiatives to facilitate the early screening of neonates. In line with this, due to the limited availability of treatment options, governments are increasing support and funding for research and development (R&D) activities to identify therapeutic agents, which is positively influencing the market growth. Furthermore, several key players are focusing on developing technologically advanced diagnostic tools and therapies to improve the efficacy and accuracy of hemophilia treatment. Along with this, extensive investments toward the establishment of specialized hemophilia treatment centers (HTC) have catalyzed market growth. Moreover, the increasing number of organizations, such as the World Federation of Hemophilia (WFH) and the National Hemophilia Foundation (NHF), that aid in discovering treatments for inheritable bleeding disorders and preventing complications through education, research, and advocacy is creating a favorable market outlook.

5. Report Description and Highlights Report Description Looking forward, IMARC Group expects the market to reach US$ 20.1 Billion by 2027, exhibiting at a CAGR of 11.5% during 2022-2027. View Report TOC, Figures and Tables: https://www.imarcgroup.com/hemophilia-market

6. Report Description and Highlights Report Description Key Market Segmentation The research report includes the following segments: Breakup by Type: •Hemophilia A •Hemophilia B •Hemophilia C •Others Breakup by Treatment: •On-Demand •Prophylaxis Breakup by Therapy: •Replacement Therapy •ITI Therapy •Gene Therapy

7. Report Description and Highlights Report Description Breakup by Region: •North America •Asia Pacific •Europe •Latin America •Middle East and Africa Competitive Landscape with Key Players: •Baxter International Inc •Bayer AG •BioMarin Pharmaceutical Inc •CSL Behring (CSL Limited) •F. Hoffmann-La Roche AG •Grifols S.A •Kedrion S.p.A •Novo Nordisk A/S •Octapharma AG •Pfizer Inc •Sanofi S.A •Takeda Pharmaceutical Company Limited

8. Key Questions Answered in the Report Report Description 1. How has the global hemophilia market performed so far and how will it perform in the coming years? What has been the impact of COVID-19 on the global hemophilia market? What are the key regional markets? What is the breakup of the market based on the type? What is the breakup of the market based on the treatment? What is the breakup of the market based on the therapy? What are the various stages in the value chain of the industry? What are the key driving factors and challenges in the industry? What is the structure of the global hemophilia market and who are the key players? 10. What is the degree of competition in the industry? 2. 3. 4. 5. 6. 7. 8. 9.

9. Report DescriptionTable of Contents 1 Preface 2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Hemophilia Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast

10. Report DescriptionTable of Contents 6 Market Breakup by Type 6.1 Hemophilia A 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Hemophilia B 6.2.1 Market Trends 6.2.2 Market Forecast 6.3 Hemophilia C 6.3.1 Market Trends 6.3.2 Market Forecast 6.4 Others 6.4.1 Market Trends 6.4.2 Market Forecast 7 Market Breakup by Treatment 7.1 On-Demand 7.1.1 Market Trends 7.1.2 Market Forecast Click here to visit the complete table of content with list of figures and tables: https://www.imarcgroup.com/hemophilia-market/toc

11. We are the trusted business partners to the world's leading corporates, governments, and institutions Partial List of Clients A partial List of our Clients

12. We are the trusted business partners to the world's leading corporates, governments, and institutions Partial List of Clients A partial List of our Clients

13. Report Description and Highlights Report Description © 2022 IMARC All Rights Reserved This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of International Market Analysis Research and Consulting (IMARC). Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication. IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.

14. Contact Us FOR MORE DETAILS Visit us at : https://www.imarcgroup.com Stay With Us: TELEPHONE: +1-631-791-1145 E-MAIL: sales@imarcgroup.com